CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 260 enrolled
Drug / intervention
Hyperbaric oxygen therapydevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03147352
NCT03147352N/ACompleted
CompareCT.gov

ProTreat - Prognosis and Treatment of Necrotizing Soft Tissue Infections: A Prospective Cohort Study

Ole Hyldegaard·observational·Posted May 10, 2017·Updated Jun 24, 2019

In Brief

An observational study evaluating Hyperbaric oxygen therapy for Necrotizing Soft Tissue Infection and 3 related conditions. Completed, enrolled 260 participants across 1 site.

Detailed Summary

The investigators will analyze biomarkers related to the prognosis and treatment of necrotizing soft tissue infections (NSTI). The focus will be on whether certain endothelial and immune system biomarkers can function as markers of disease severity, mortality as well as the effects of hyperbaric oxygen therapy (HBOT). Biomarkers will be measured upon admission to an intensive care unit at Copenhagen University Hospital and during the following 3 days.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNecrotizing Soft Tissue Infection, Necrotizing Fascitis, Gas Gangrene, Fournier Gangrene
CountriesDenmark
CollaboratorsSeventh Framework Programme

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMay 10, 2017
Enrollment StartFeb 1, 2013
Primary CompletionJan 1, 2018
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 9.1 years ago

Interventions

Hyperbaric oxygen therapydevice

Hyperbaric oxygen therapy with 100 % oxygen at 1.8 ATA for 2 hours.